Toinv - I have been thinking in the same terms as you. It would be nice to see a DSMB report for RVX and even nicer if there is a futility study attached.

As far as Zenith and GAC's conversation with DM in Toronto the timing would now be bang on. Interestingly the 12th of September is just over 1.5yrs that the rock stars in the second cohort would be on ZEN3694. Don's comment to GAC about him reminding big pharma that their revenue being extended by using our drug in combination with theirs would then represent about $9 billion of additional sales for their drugs at that time.

Looking forward to an updated presentation for RVX at the AGM and the items we will be voting on for Zenith in the meeting notice material.

dyodd

tada